Pfizer surged past the target price from our last report as the company had strong third quarter, with a 130% increase in operational revenue compared to 2020. Its operational revenue grew by 7% compared to the previous year's quarter even after excluding direct sales and alliance revenues from their Covid-19 vaccine. The company is on track to create 3 billion doses this year, with at least 1 billion going to low-income and middle-income countries. Additionally, their weekly market share of Cov ....
